People with Chronic Kidney Disease often experience systemic inflammation, increasing their susceptibility to severe cardiovascular events. Inflammation is a driver for the progression of atherosclerosis, which involves the accumulation of fats, cholesterol, and other substances within the walls of arteries.
This inflammatory process can pose significant risks for individuals with Atherosclerotic Cardiovascular Disease (ASCVD), more commonly known as “heart disease.” Heart disease is one of the leading causes of illness and death among people globally. This emphasizes the need for ongoing research and innovation in heart disease management, aiming to improve treatment outcomes and also streamline the lives of individuals living with these conditions.
St. Johns Center for Clinical Research is conducting a study that will evaluate an investigational medication for patients with both heart disease and chronic kidney disease. The purpose of this study is to evaluate the effectiveness of an investigational once-monthly injection compared to placebo in reducing the risk of major cardiovascular events when added to standard of care treatment.
You may be eligible if you:
- Are 18 years or older
- Have Chronic Kidney Disease (CKD)
- Have evidence of ASCVD by one or more of the following criteria:
- Documented history of a heart attack
- Prior coronary revascularization procedure (CABG, PCI, or Stent Placement)
- Prior stroke
- Prior carotid endarterectomy
- Peripheral Artery Disease (symptomatic)
There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and medical exams at no cost, along with a stipend for time and travel. No health insurance is required to participate.
For more information call
This research is enrolling at:
BELOW ARE HIDDEN ROWS
- St. Augustine